The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of pathological stratification of advanced well differentiated/dedifferentiated (WD/DD) liposarcoma (LPS) on the response to trabectedin (T).
 
Roberta Sanfilippo
Consulting or Advisory Role - Lilly; PharmaMar
 
Elena Fumagalli
No Relationships to Disclose
 
Paola Collini
No Relationships to Disclose
 
Giovanni Fucà
No Relationships to Disclose
 
Salvatore Lorenzo Renne
No Relationships to Disclose
 
Marta Barisella
No Relationships to Disclose
 
Rossella Bertulli
No Relationships to Disclose
 
Salvatore Provenzano
No Relationships to Disclose
 
Carlo Morosi
No Relationships to Disclose
 
Alessandro Gronchi
Honoraria - Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar
 
Angelo Paolo Dei Tos
Honoraria - Eisai; Lilly; Pfizer; PharmaMar
Consulting or Advisory Role - Eisai; Lilly
 
Paolo Giovanni Casali
Honoraria - Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - ARIAD/Merck; Bayer; Blueprint Medicines; Eisai; GlaxoSmithKline; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; PharmaMar
Research Funding - Amgen/Dompé (Inst); Bayer (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MolMed (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar